Robert Schilz, DO
- Director, Pulmonary Vascular Disease Program, UH Cleveland Medical Center
- Associate Professor, CWRU School of Medicine
- Specialty: Pulmonary Disease
-
Location:UH Cleveland Medical Center Bolwell
11100 Euclid Ave
Cleveland, OH 44106
- Call: 216-844-8500
Biography: Robert Schilz, DO
Expertise
Education
Fellowship | Pulmonary/Critical Care
Pulmonary/Critical Care - Yale University School Of Medicine (1993 - 1996)
Residency | Internal Medicine/Chief Resident
Internal Medicine/Chief Resident - Cleveland Clinic (1992 - 1993)
Residency | Internal Medicine
Internal Medicine - Cleveland Clinic (1989 - 1992)
Internship | Internal Medicine
Internal Medicine - Sparrow Hospital (1988 - 1989)
Medical Education
Michigan State University College Of Human Medicine (1988)
Undergraduate
University Of Wisconsin-Madison (1979)
About
Dr. Robert Schilz is director of the Pulmonary Vascular Disease Program at University Hospitals Cleveland Medical Center. He is also an Associate Professor at Case Western Reserve University School of Medicine.
Dr. Schilz earned Doctor of Osteopathic Medicine (DO) and Doctor of Philosophy (PhD) degrees from the Michigan State University Medical Scientist Training program. He then completed a Residency and Chief Residency at the Cleveland Clinic in Cleveland, Ohio. He also completed Pulmonary & Critical Care and Research fellowships at Yale University. Prior to joining University Hospitals, Dr. Schilz was on staff at the Cleveland Clinic in Pulmonary and Critical Care Medicine.
For over 25 years, Dr. Schilz has participated in clinical and basic research in the areas of advanced lung diseases and pulmonary hypertension, with numerous publications in the areas of pulmonary hypertension, lung transplantation and advanced lung disease.
Dr. Schilz serves or has served as an advisor or committee member for a number of state, national and international organizations, including the International Society for Heart Lung Transplantation, American College of Chest Physicians, Pulmonary Hypertension Association and the Ohio State Board of Hospitals. He is a past Associate Editor of Advances in Pulmonary Hypertension and reviewer for a number of international journals. He has been consistently named as “One of America’s Best Doctors” since 2005.
Featured Videos
Watch to find out more about this University Hospitals provider.
Industry Relationships
University Hospitals is committed to transparency in our interactions with industry partners, such as pharmaceutical, biotech, or medical device companies. At UH, we disclose practitioner and their family members’ ownership and intellectual property rights that are or in the process of being commercialized. In addition, we disclose payments to employed practitioners of $5,000 or more from companies with which the practitioners interact as part of their professional activities. These practitioner-industry relationships assist in developing new drugs, devices and therapies and in providing medical education aimed at improving quality of care and enhancing clinical outcomes. At the same time, UH understands that these relationships may create a conflict of interest. In providing this information, UH desires to assist patients in talking with their practitioners about industry relationships and how those relationships may impact their medical care.
UH practitioners seek advance approval for certain new industry relationships. In addition, practitioners report their industry relationships and activities, as well as those of their immediate family members, to the UH Office of Outside Interests annually. We review these reports and implement management plans, as appropriate, to address conflicts of interest that may arise in connection with medical research, clinical care and purchasing decisions.
View UH’s policy (PDF) on practitioner-industry relationships.
As of December 31, 2016, Robert Schilz disclosed the following Outside Relationships with Industry:
- - Gilead - Consulting
- - SCS Healthcare - Consulting
- - United Therapeutics Corp - Consulting
- - Actelion Ltd. - Honoraria
- - Bayer Corporation - Honoraria
- - Genentech, Inc. - Honoraria